At Centauri we seek to tackle life-threatening infectious diseases in the most vulnerable patients.

Learn more
Alphamers

Our science

Centauri Therapeutics is an immunotherapy company currently focused on infectious diseases. Centauri’s approach to treating infectious diseases rests upon proprietary Alphamer® technology. All projects harness a powerful and clinically validated immune mechanism which redirects naturally existing antibodies to treat life-threatening diseases.

7.0m

immunocompromised people in the United States 1

60%

of haematological cancer deaths are infection related 2

$4.6bn

health care costs in the US to treat six antibiotic resistance threats 3

67,000

deaths annually in Europe and US due to drug-resistant bacterial infections 4 5

Bacteria

Latest News and Articles

Centauri Team Building Day at Jodrell Bank

August 17, 2023

We enjoyed a Company Team Day at Jodrell Bank in…

Read More
Group of people smiling

Race For Life 2023

July 19, 2023

Centauri Therapeutics Fundraising Team really enjoyed their first event ‘Race…

Read More

BIA Life Sciences Leadership Summit

June 30, 2023

On 19- 20 June, our CEO Jen, and VP of…

Read More

Citations

1. https://www.ama-assn.org/delivering-care/public-health/what-tell-immunocompromised-patients-about-covid-19-vaccines

2. Zembower, T.R. (2014). Epidemiology of Infections in Cancer Patients. In: Stosor, V., Zembower, T. (eds) Infectious Complications in Cancer Patients. Cancer Treatment and Research, vol 161. Springer, Cham https://doi.org/10.1007/978-3-319-04220-6_2

3. https://www.cdc.gov/drugresistance/solutions-initiative/stories/partnership-estimates-healthcare-cost.html

4. https://www.euro.who.int/en/health-topics/disease-prevention/pages/news/news/2022/01/whoecdc-report-antimicrobial-resistance-remains-threat-to-health-in-european-region

5. https://archive.cdc.gov/#/details?url=https://www.cdc.gov/media/releases/2019/p1113-antibiotic-resistant.html